Moomoo AI 已提取核心訊息
On February 13, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, issued a shareholder update via press release, detailing significant operational achievements and outlining future milestones. The company, listed on NASDAQ under the symbol TCBP, announced FDA clearance for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML) and a collaboration with Queen Mary University of London to expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases. TC BioPharm also reported an approximate $11.6 million in cost-savings and the successful completion of the ACHIEVE Study safety cohort. Additionally, the company filed a preliminary proxy statement with the SEC on February 9, 2024, seeking shareholder approval for a potential issuance of shares that could exceed 20% of the outstanding shares at a discounted price, in accordance with Nasdaq Marketplace Rule 5635(d). The Board of Directors has not yet determined the terms of any potential financing. The company emphasized its focus on strategic partnerships and budget savings for the year ahead.
On February 13, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, issued a shareholder update via press release, detailing significant operational achievements and outlining future milestones. The company, listed on NASDAQ under the symbol TCBP, announced FDA clearance for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML) and a collaboration with Queen Mary University of London to expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases. TC BioPharm also reported an approximate $11.6 million in cost-savings and the successful completion of the ACHIEVE Study safety cohort. Additionally, the company filed a preliminary proxy statement with the SEC on February 9, 2024, seeking shareholder approval for a potential issuance of shares that could exceed 20% of the outstanding shares at a discounted price, in accordance with Nasdaq Marketplace Rule 5635(d). The Board of Directors has not yet determined the terms of any potential financing. The company emphasized its focus on strategic partnerships and budget savings for the year ahead.
2024年2月13日，處於臨床階段的生物製藥公司TC Biopharm（Holdings）PLC通過新聞稿發佈了股東最新情況，詳細介紹了重大運營成就並概述了未來的里程碑。該公司在納斯達克上市，股票代碼爲TCBP，宣佈美國食品藥品管理局批准一項針對復發/難治性急性髓系白血病（AML）的1B期研究，並與倫敦瑪麗皇后大學合作，將其 TCB-008 療法擴展到抗真菌和抗菌疾病。TC BioPharm還報告說，節省了約1160萬美元的成本，併成功完成了ACHIEVE研究安全隊列。此外，該公司於2024年2月9日向美國證券交易委員會提交了初步委託書，根據納斯達克市場規則5635（d），尋求股東批准可能以折扣價發行可能超過已發行股票20％的股票。董事會尚未確定任何潛在融資的條款。該公司強調將重點放在未來一年的戰略伙伴關係和預算節省上。
2024年2月13日，處於臨床階段的生物製藥公司TC Biopharm（Holdings）PLC通過新聞稿發佈了股東最新情況，詳細介紹了重大運營成就並概述了未來的里程碑。該公司在納斯達克上市，股票代碼爲TCBP，宣佈美國食品藥品管理局批准一項針對復發/難治性急性髓系白血病（AML）的1B期研究，並與倫敦瑪麗皇后大學合作，將其 TCB-008 療法擴展到抗真菌和抗菌疾病。TC BioPharm還報告說，節省了約1160萬美元的成本，併成功完成了ACHIEVE研究安全隊列。此外，該公司於2024年2月9日向美國證券交易委員會提交了初步委託書，根據納斯達克市場規則5635（d），尋求股東批准可能以折扣價發行可能超過已發行股票20％的股票。董事會尚未確定任何潛在融資的條款。該公司強調將重點放在未來一年的戰略伙伴關係和預算節省上。
有用
沒用